These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33788326)

  • 21. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction?
    de Vos AS; van der Helm JJ; Matser A; Prins M; Kretzschmar ME
    Addiction; 2013 Jun; 108(6):1070-81. PubMed ID: 23347124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimating the number of people who inject drugs and syringe coverage in Australia, 2005-2016.
    Kwon JA; Iversen J; Law M; Dolan K; Wand H; Maher L
    Drug Alcohol Depend; 2019 Apr; 197():108-114. PubMed ID: 30802734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada.
    Jacka B; Larney S; Degenhardt L; Janjua N; Høj S; Krajden M; Grebely J; Bruneau J
    Am J Public Health; 2020 Jan; 110(1):45-50. PubMed ID: 31725310
    [No Abstract]   [Full Text] [Related]  

  • 24. Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review.
    Degenhardt L; Webb P; Colledge-Frisby S; Ireland J; Wheeler A; Ottaviano S; Willing A; Kairouz A; Cunningham EB; Hajarizadeh B; Leung J; Tran LT; Price O; Peacock A; Vickerman P; Farrell M; Dore GJ; Hickman M; Grebely J
    Lancet Glob Health; 2023 May; 11(5):e659-e672. PubMed ID: 36996857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration.
    Morris MD; Shiboski S; Bruneau J; Hahn JA; Hellard M; Prins M; Cox AL; Dore G; Grebely J; Kim AY; Lauer GM; Lloyd A; Rice T; Shoukry N; Maher L; Page K;
    Clin Infect Dis; 2017 Apr; 64(7):860-869. PubMed ID: 28362947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infections among people who inject drugs in Kuwait: A cross-sectional study.
    Altawalah H; Essa S; Ezzikouri S; Al-Nakib W
    Sci Rep; 2019 Apr; 9(1):6292. PubMed ID: 31000775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seroprevalence of HIV, hepatitis b, and hepatitis c among opioid drug users on methadone treatment in the netherlands.
    Schreuder I; van der Sande MA; de Wit M; Bongaerts M; Boucher CA; Croes EA; van Veen MG
    Harm Reduct J; 2010 Oct; 7():25. PubMed ID: 20977742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico.
    Marquez LK; Fleiz C; Burgos JL; Cepeda JA; McIntosh C; Garfein RS; Kiene SM; Brodine S; Strathdee SA; Martin NK
    Addiction; 2021 Oct; 116(10):2734-2745. PubMed ID: 33620750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
    Akiyama MJ; Cleland CM; Lizcano JA; Cherutich P; Kurth AE
    Lancet Infect Dis; 2019 Nov; 19(11):1255-1263. PubMed ID: 31540840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in HIV incidence among people who inject drugs in Taiwan following introduction of a harm reduction program: a study of two cohorts.
    Huang YF; Yang JY; Nelson KE; Kuo HS; Lew-Ting CY; Yang CH; Chen CH; Chang FY; Liu HR
    PLoS Med; 2014 Apr; 11(4):e1001625. PubMed ID: 24714449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin.
    Stark K; Bienzle U; Vonk R; Guggenmoos-Holzmann I
    Int J Epidemiol; 1997 Dec; 26(6):1359-66. PubMed ID: 9447418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. M
    Martel-Laferrière V; Feaster DJ; Metsch LR; Schackman BR; Loignon C; Nosyk B; Tookes H; Behrends CN; Arruda N; Adigun O; Goyer ME; Kolber MA; Mary JF; Rodriguez AE; Yanez IG; Pan Y; Khemiri R; Gooden L; Sako A; Bruneau J
    Trials; 2022 Apr; 23(1):341. PubMed ID: 35461260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modeling the Impacts of Prevention and Treatment Interventions on Hepatitis C Among People Who Inject Drugs in China.
    Fang K; Wang HL; Lin Y; Li S; Wu J
    Infect Dis Ther; 2023 Apr; 12(4):1043-1055. PubMed ID: 36894824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of high-risk drug use and coverage of opioid substitution treatment and needle and syringe programs in Lithuania in 2015-2016: A multi-method estimation study.
    Thanki D; Mravčík V; Běláčková V; Mačiulytė D; Zábranský T; Širvinskienė A; Subata E; Lorenzo-Ortega R
    J Subst Abuse Treat; 2021 Mar; 122():108229. PubMed ID: 33509418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of on-site and outreach-based needle and syringe programs in people who inject drugs in Kermanshah, Iran.
    Nazari SS; Noroozi M; Soori H; Noroozi A; Mehrabi Y; Hajebi A; Sharifi H; Higgs P; Mirzazadeh A
    Int J Drug Policy; 2016 Jan; 27():127-31. PubMed ID: 26764125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. WHO guidance on the prevention of viral hepatitis B and C among people who inject drugs.
    Walsh N; Verster A; Rodolph M; Akl EA
    Int J Drug Policy; 2014 May; 25(3):363-71. PubMed ID: 24561223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
    Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
    Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness.
    MacArthur GJ; van Velzen E; Palmateer N; Kimber J; Pharris A; Hope V; Taylor A; Roy K; Aspinall E; Goldberg D; Rhodes T; Hedrich D; Salminen M; Hickman M; Hutchinson SJ
    Int J Drug Policy; 2014 Jan; 25(1):34-52. PubMed ID: 23973009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Public health interventions, priority populations, and the impact of COVID-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada): A modeling study.
    Lanièce Delaunay C; Klein MB; Godin A; Cox J; Kronfli N; Lebouché B; Doyle C; Maheu-Giroux M
    Int J Drug Policy; 2023 Jun; 116():104026. PubMed ID: 37075626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV and hepatitis B and C co-infection among people who inject drugs in Zanzibar.
    Khatib A; Matiko E; Khalid F; Welty S; Ali A; Othman A; Haji S; Dahoma M; Rutherford G
    BMC Public Health; 2017 Nov; 17(1):917. PubMed ID: 29183287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.